Señales en vivo de NTLA | Maximiza tus Ganancias con Getagraph.com

COMPRAR 79775 min ago

@ $29.86

Emitido: 11 mar 2024 @ 11:11

Retorno: -20.96%

Señal anterior: mar 11 - 09:31

Señal anterior: Vender

Retorno: -1.35 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	1.29M
Volumen promedio	1.48M
Capitalización de mercado	2.28B
EPS	$0 ( 2024-05-02 )
Próxima fecha de ganancias	( $-1.350 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.35
ATR14	$0.0260 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Dube Michael P	Sell	0	Common Stock
2024-03-01	Sepp-lorenzino Laura	Buy	37 966	Common Stock
2024-03-01	Sepp-lorenzino Laura	Buy	54 794	Stock Option (right to buy)
2024-03-01	Basta James	Buy	32 394	Common Stock
2024-03-04	Basta James	Sell	2 297	Common Stock

INSIDER POWER
85.54
Last 100 transactions
Buy: 1 561 723 \| Sell: 123 854

Volumen Correlación

Largo: 0.15 (neutral)

Corto: -0.81 (strong negative)

Signal:(52.823) Neutral

Intellia Therapeutics Inc Correlación

10 Correlaciones Más Positivas
PYCR	0.85
NVIV	0.838
RKDA	0.833
BIOC	0.826
LAZY	0.822
CDZI	0.82
HUGE	0.818
SBUX	0.818
TNXP	0.806
RGP	0.804

10 Correlaciones Más Negativas
UIHC	-0.813

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intellia Therapeutics Inc Correlación - Moneda/Commodity

0.47
( neutral )

0.45
( neutral )

0.00
( neutral )

0.56
( weak )

-0.52
( weak negative )

Intellia Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$36.28M
Beneficio Bruto:	$27.30M (75.26 %)
EPS:	$-5.42

FY	2023
Ingresos:	$36.28M
Beneficio Bruto:	$27.30M (75.26 %)
EPS:	$-5.42

FY	2022
Ingresos:	$52.12M
Beneficio Bruto:	$44.55M (85.47 %)
EPS:	$-6.37

FY	2021
Ingresos:	$33.05M
Beneficio Bruto:	$33.05M (100.00 %)
EPS:	$-3.78

Financial Reports:

No articles found.

Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Actualizaciones en tiempo real para Intellia Therapeutics Inc [NTLA]

Upcoming Earnings Alert